Chief Strategy Officer — Diagnostic-Services Platform

The mandate

A diagnostic-services group has acquired a regional platform with complementary laboratories, imaging access and provider contracts. The transaction creates valuable reach but also overlapping test menus, duplicated equipment plans and divergent quality systems. The board has created an urgent new Chief Strategy Officer role to translate the acquisition thesis into explicit choices before local integration work fixes the wrong future state.

Approximately 900 employees and material partners span collection, laboratories, imaging, specialist interpretation, technology and commercial functions in Singapore and the wider region. The CSO owns enterprise strategy, portfolio choices, integration thesis, strategic partnerships and transaction evaluation, reporting to the Group Chief Executive or nominated sponsor. Clinical and quality leaders retain professional authority.

The first decision is the network role of each site. Laboratories differ in specialist capability, equipment, accreditation, logistics and cost. The CSO will model which work should remain local, consolidate, become a regional centre or move to a partner. Turnaround, specimen stability, resilience and clinical access belong beside contribution in every recommendation.

Test-menu integration requires more than deleting duplicate codes. Methods, reference ranges, instruments and reporting conventions may differ. Strategy must recognise the cost and time of harmonisation, clinician communication and regulatory approval. A commercial promise of one menu is not real until laboratories can deliver comparable, governed results.

The acquisition case includes digital ordering and result access. These capabilities may increase referrals but also require provider adoption, identity matching, interface investment and support. The CSO will define where digital integration creates genuine pathway value and where a lightweight interoperability partnership is more sensible than full platform replacement.

Payer and provider contracts need portfolio analysis. Some agreements reward local reach, others specialist turnaround or bundled pathways. The acquired footprint may improve negotiation leverage while creating volume commitments. The CSO will identify which contracts should be renewed, consolidated, repriced or exited, with operational capacity and continuity considered.

Synergies will be validated independently. Procurement, equipment, logistics, facilities and corporate functions each contain opportunity, but assumptions overlap. The strategy office will maintain one baseline, owner, dependency and decision date. Savings requiring clinical or regulatory change will not be counted before that pathway is approved.

Growth choices must be selective. Molecular diagnostics, pathology subspecialties, imaging and preventive testing present different evidence and capital profiles. The CSO will establish criteria based on unmet clinical need, payer acceptance, workforce, equipment, data and route to scale. Market enthusiasm will not substitute for a viable sample or patient pathway.

Partnerships can extend capability without duplicating capital. Academic centres, hospitals, technology firms and specialist laboratories may contribute interpretation, validation or access. The CSO will ensure governance covers quality, data, result responsibility, intellectual property and exit. A referral partnership without reliable turnaround and escalation is not strategic capacity.

Integration sequencing matters. Consolidating logistics before data and test rules are stable may create routing errors; combining customer teams before account ownership is clear may disrupt providers. The CSO will create dependency-based waves and state the conditions that permit each move. Sunk cost will not justify proceeding through a failed gate.

Capital allocation will follow the target network. Equipment replacement, automation and new facilities must support a defined role. The CSO will challenge local requests that preserve autonomy without network value and equally challenge centralisation whose savings ignore continuity. Option value may justify temporary parallel capacity during harmonisation.

The strategy function will stay close to delivery without becoming a programme office. It will own the thesis, decisions and value logic; accountable executives will implement. When operating evidence contradicts the case, the CSO must revisit the choice rather than defend the original presentation.

Board materials will show alternatives, uncertainties and triggers. The board needs to know what must be true, what is reversible and what decision cannot wait. Strategy will be measured by funded choices and stopped activity, not the number of market analyses completed.

What you will own

• Diagnostic network and portfolio strategy.
• Acquisition thesis, synergy baseline and decision gates.
• Test-menu, site and capability choices.
• Payer, provider and partnership strategy.
• Growth adjacency and strategic transaction evaluation.
• Capital allocation with finance and operations.
• Board choices and implementation feedback.
• Strategy talent and succession.

The first 12 months

In the first 45 days, reconstruct the acquisition case, map site and test capabilities and identify integration actions proceeding without a settled target state. Escalate any move that could impair diagnostic continuity.

By month six, approve the network role, test-menu sequence and contract priorities. Reallocate capital, confirm partnerships and stop lower-conviction growth initiatives.

At twelve months, verify SGD 60 million of annualised integration value without duplicate counting, reduce overlapping capital commitments by 25% and complete 90% of first-wave harmonisation gates on time. Priority turnaround should not deteriorate through consolidation, and every retained site and growth programme must have a board-agreed strategic role.

What the sponsor will examine

• Site roles grounded in clinical and logistic reality.
• Test harmonisation preceding commercial simplification.
• Digital value including adoption and identity costs.
• Synergies counted after relevant approvals.
• Integration waves respecting true dependencies.
• Capital removed from activity outside the thesis.

The person

You bring 22–28 years in healthcare strategy, diagnostics, transactions or portfolio leadership, including post-acquisition integration across Asian markets. Your record includes laboratory or imaging network choices, material capital allocation and board-level decisions under regulatory and clinical constraints.

Candidates should demonstrate a synergy they challenged and a strategic programme they stopped after evidence changed. Singapore is the permanent onsite base, with significant regional travel and partner engagement.

Compensation and terms

Base compensation is SGD 420,000–570,000 plus annual incentive and long-term participation linked to verified integration value, portfolio quality, capital choices, continuity and strategy leadership. The permanent onsite Singapore role reports to the Group Chief Executive or nominated executive-committee sponsor. Appointment is urgent while integration choices remain open.

Confidentiality

The group, acquired platform, laboratories, providers, payers, transaction case and integration plans remain confidential. Further material follows conflicts and signed confidentiality. Applicants must not contact diagnostic businesses or advisers to identify the parties.